Table 2.

Rate of change of FEV1 categorized by beta-agonist subtype in patients receiving sirolimus

Beta-agonist typeFEV1 rate of change, mean percent predicted per year ± SE
None−1.297 ± 0.371 (122 visits)
Beta-agonist0.125 ± 0.288 (187 visits)
P = 0.002
None−1.311 ± 0.346 (122 visits)
Short-acting−0.393 ± 0.665 (48 visits)
Both short-acting and long-acting0.493 ± 0.365 (104 visits)
Long-acting0.880 ± 0.782 (35 visits)
N vs. SP = 0.2253
N vs. SLP = 0.0004
N vs. LP = 0.0113
S vs. SLP = 0.2399
S vs. LP = 0.2103
SL vs. LP = 0.6525
  • With statistical correction, significant P values are those less than 0.0083. L, long-acting beta-agonist; N, no beta agonist; S, short-acting beta-agonist; SL, short- and long-acting beta-agonists.